Condition: Moderately to Severely Active Crohns Disease · Sponsor: Hoffmann-La Roche
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
This description comes directly from the study's public registry record.
Reference Study ID Number: CP45906 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Royal Children's Hospital | Parkville, Victoria, Australia | Recruiting |
| Perth Children's Hospital | Nedlands, Western Australia, Australia | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Chulalongkorn University | Bangkok, Thailand | Recruiting |
| Siriraj Hospital | Bangkok, Thailand | Recruiting |
| Ramathibodi Hospital | Bangkok, Thailand | Recruiting |
| Sheffield Childrens Hospital | Sheffield, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07298421